SIGA Technologies Q2 2024 Earnings Report $6.22 -0.02 (-0.32%) As of 01/17/2025 04:00 PM Eastern Earnings History SIGA Technologies EPS ResultsActual EPS$0.03Consensus EPS N/ABeat/MissN/AOne Year Ago EPS-$0.04SIGA Technologies Revenue ResultsActual Revenue$21.81 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASIGA Technologies Announcement DetailsQuarterQ2 2024Date8/1/2024TimeAfter Market ClosesConference Call ResourcesConference CallConference Call TranscriptPress ReleaseSIGA Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by SIGA Technologies Earnings HeadlinesSiga Technologies approved in Japan for treatment of orthopoxvirusesJanuary 2, 2025 | markets.businessinsider.comSIGA Technologies Inc.: TEPOXX (tecovirimat) Approved in Japan for the Treatment of OrthopoxvirusesJanuary 2, 2025 | finanznachrichten.deFree Stock Ticker Inside: This Indicator Caught Nvidia’s RalliesI’m not one to make super bold statements… But today, I’m making an exception. Because I’m 100% convinced this is the best indicator I’ve used for trading Nvidia… Don’t believe me? Just take a look at the last two rallies: This powerful indicator caught both moves almost perfectly.January 21, 2025 | ProsperityPub (Ad)SIGA wins Japan approval for mpox therapy TepoxxJanuary 2, 2025 | msn.comSIGA's Tepoxx Gets Regulatory Approval In Japan For Treatment Of OrthopoxvirusesJanuary 2, 2025 | markets.businessinsider.comTEPOXX (tecovirimat) Approved in Japan for the Treatment of OrthopoxvirusesJanuary 2, 2025 | globenewswire.comSee More SIGA Technologies Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like SIGA Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SIGA Technologies and other key companies, straight to your email. Email Address About SIGA TechnologiesSIGA Technologies (NASDAQ:SIGA), a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.View SIGA Technologies ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings ICICI Bank (1/22/2025)Kinder Morgan (1/22/2025)Amphenol (1/22/2025)Abbott Laboratories (1/22/2025)Johnson & Johnson (1/22/2025)Procter & Gamble (1/22/2025)Travelers Companies (1/22/2025)Progressive (1/22/2025)GE Vernova (1/22/2025)CSX (1/23/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
